BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The October 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a focus feature on those active in Neuro-partnering. This week, find out about how you can collaborate with Enkam Pharmaceuticals A/S.
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.
Click here for more information on Alzheimer's partnering opportunities.
SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
Translating autism Kai-Jye Lou doi:10.1038/scibx.2012.1248 Researchers at McGill University have mouse data showing a causal link between eIF4E-mediated translational dysregulation and autism-related deficits. The group also corrected the dysregulation—and the associated autistic phenotype—with a small molecule. Full Text | PDF
Quebec's research resurrection Lev Osherovich doi:10.1038/scibx.2012.1249 A shuttered AstraZeneca research center in Montreal has reemerged as Neomed, a public-private partnership between AstraZeneca, Pfizer and the government of Quebec. The institute will continue to develop AstraZeneca's pain compounds and plans to grow its pipeline with regional partnerships. Full Text | PDF
Muscling up on Myozyme Tim Fulmer doi:10.1038/scibx.2012.1250 Oxyrane and BioMarin have separately reported on their next-generation enzyme replacement therapies for Pompe's disease. Both molecules cleared glycogen from mouse muscle better than the marketed drug Myozyme from Sanofi. Full Text | PDF
Pulmonary edema on a chip Lauren Martz doi:10.1038/scibx.2012.1251 Researchers at the Wyss Institute have described an organ-on-a-chip microfluidic model of pulmonary edema that could be better than culture models at predicting whether therapeutics will translate to humans. The team already has used the model in proof-of-concept studies to test potential pulmonary edema therapeutic candidates and wants to expand the use of the chip to model multiple lung diseases. Full Text | PDF
Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335); natural killer p30 receptor (NKp30; NCR3; CD337) doi:10.1038/scibx.2012.1252 Mouse and cell culture studies suggest inhibiting NCR1 or NCR3 could enhance oncolytic viral therapies to treat glioblastoma. Full Text | PDF
Epsin 1 (EPN1); EPN2 doi:10.1038/scibx.2012.1253 Mouse studies suggest inhibiting EPN1 and EPN2 could help treat cancer. Full Text | PDF
Retinoid X receptor-α (RXRA; RXRα); tumor necrosis factor-α (TNF-α) doi:10.1038/scibx.2012.1254 Cell culture studies suggest a xanthone called CF31, isolated from the Cratoxylum formosum plant, could be useful for treating cancer. Full Text | PDF
Oncostatin M (OSM) doi:10.1038/scibx.2012.1255 Mouse studies suggest the cytokine OSM could help treat lung cancer. Full Text | PDF
Not applicable doi:10.1038/scibx.2012.1256 A clinical study suggests gastric bypass and gastric banding lead to equivalent and weight loss–dependent improvements in insulin sensitivity and β cell function. Full Text | PDF
Phosphoenolpyruvate carboxykinase 1 (PCK1) doi:10.1038/scibx.2012.1257 A zebrafish screening study identified metabolic activators that could protect against obesity-related metabolic dysregulation. Full Text | PDF
Wingless-type MMTV integration site family member 7A (WNT7A) doi:10.1038/scibx.2012.1258 Mouse studies suggest increasing WNT7A signaling could help treat muscular dystrophy. Full Text | PDF
Glycogen synthase kinase 3β (GSK3B) doi:10.1038/scibx.2012.1259 Mouse studies suggest inhibiting GSK3B could help treat DM1. Full Text | PDF
Amyloid precursor protein (APP) doi:10.1038/scibx.2012.1260 Studies in mice suggest preventing the accumulation of the C99 peptide fragment of APP could help prevent or treat AD. Full Text | PDF
Arrestin β2 (ARRB2) doi:10.1038/scibx.2012.1261 In vitro and mouse studies suggest antagonizing ARRB2 could help treat AD. Full Text | PDF
Glycogen dependent kinase 3 (GSK3) doi:10.1038/scibx.2012.1262 Mouse studies suggest inhibiting GSK3 could help to treat AD. Full Text | PDF
IL-12; IL-23 doi:10.1038/scibx.2012.1263 Patient sample and mouse studies suggest inhibiting IL-12 and IL-23 signaling could help treat AD. Full Text | PDF
SRSF protein kinase 2 (SRPK2) doi:10.1038/scibx.2012.1264 Human sample and mouse studies suggest inhibiting SRPK2 signaling could help treat AD. Full Text | PDF
GABAA receptor doi:10.1038/scibx.2012.1265 In vitro and clinical studies suggest GABAA receptor inhibitors could help treat hypersomnias (excessive sleepiness). Full Text | PDF
Platelet derived growth factor A (PDGFA; PDGF1) doi:10.1038/scibx.2012.1266 A study in mice suggests lithium could help treat neonatal hydrocephalus, an expansion of the cerebral ventricles. Full Text | PDF
Antibiotic mode of action profile (BioMAP) screening to identify and classify antibiotics in natural product extracts doi:10.1038/scibx.2012.1267 Comparing the inhibitory profiles of natural product extracts with those of known classes of antibiotics could help identify new antibiotic leads. Full Text | PDF
Design of Genuine Structures (DOGS) software for de novo computer-assisted drug design doi:10.1038/scibx.2012.1268 A computational software package called DOGS could be useful for discovering new therapeutic leads to treat cancer and other diseases. Full Text | PDF
Mouse model for invasive lobular breast cancer metastasis doi:10.1038/scibx.2012.1269 A mouse model for invasive lobular breast cancer metastasis could aid the understanding of metastasis and help test new therapeutic candidates. Full Text | PDF
Boosting antitumor immune response by blocking glycolysis doi:10.1038/scibx.2012.1270 A study in mice suggests blocking glycolysis with a small molecule could help enhance an antitumor immune response. Full Text | PDF
Insulin-like growth factor-2 (IGF-2) peptide tag to improve enzyme replacement therapies to treat Pompe's disease doi:10.1038/scibx.2012.1271 A lysosome-targeting peptide tag may be useful for producing Pompe's disease enzyme replacement therapies that have better tissue uptake than unmodified acid α-glucosidase (GAA). Full Text | PDF
Yeast cell lines for producing improved enzyme replacement therapies to treat Pompe's disease doi:10.1038/scibx.2012.1272 Genetically modified strains of the yeasts Yarrowia lipolytica and Pichia pastoris may be useful for producing Pompe's disease enzyme replacement therapies that have better tissue uptake than unmodified acid α-glucosidase (GAA). Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment